CytoDyn Inc. reports Q3 2026 loss
- Net loss of $19.9 million for Q3 2026
- Cash and cash equivalents increased to $16.4 million as of August 31, 2026
- Accrued liabilities and compensation totaled $14.5 million as of August 31, 2026
Every EDGAR filing for CytoDyn Inc. (CYDY), newest first, with AI summaries and stories.
Next: 10-Q expected ~Jan 14 (deadline Jan 14)
Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.
Tanya Durkee Urbach, insider filing for CYDY
Tanya Durkee Urbach, reporting